There’s no doubt that CAR-T therapies have transformed the treatment of many blood cancers, but a risk of secondary malignancies has cast a pall over the class.
AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy.
Bristol-Myers Squibb has chalked up another FDA approval for its CD19-directed CAR-T therapy Breyanzi, this time as a third-line or later therapy for follicular lymphoma (
Astellas has clearly been impressed with a partnership signed last August with Poseida Therapeutics on the development of cell therapies for solid tumours, as it has just
Bristol-Myers Squibb has shored up manufacturing of its CAR-T therapies, tapping into capacity at contract manufacturer Cellares that will be used to supply patients in th
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh